(Q38054543)

27 August 2017

Possible roles of IL-12-family cytokines in rheumatoid arthritis (English)

1 reference

27 August 2017

0 references

Richard M Pope

1

0 references

author name string

Shiva Shahrara

series ordinal

2

1 reference

PubMed ID

23090510

27 August 2017

language of work or name

English

0 references

publication date

23 October 2012

1 reference

Nature Reviews Rheumatology

27 August 2017

1 reference

27 August 2017

9

1 reference

27 August 2017

4

1 reference

27 August 2017

252-256

1 reference

https://scigraph.springernature.com/pub.10.1038/nrrheum.2012.170

27 August 2017

0 references

cites work

Interleukin-35: odd one out or part of the family?

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.170

Interleukin-12 and the regulation of innate resistance and adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.170

The composition and signaling of the IL-35 receptor are unconventional

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.170

New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.170

IL-17 family cytokines and the expanding diversity of effector T cell lineages

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.170

Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.170

The elevated ratio of interferon gamma-/interleukin-4-positive T cells found in synovial fluid and synovial membrane of rheumatoid arthritis patients can be changed by interleukin-4 but not by interleukin-10 or transforming growth factor beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.170

TH-17 cells in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.170

Administration of interleukin 12 in combination with type II collagen induces severe arthritis in DBA/1 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.170

Signalling, inflammation and arthritis: crossed signals: the role of interleukin (IL)-12, -17, -23 and -27 in autoimmunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.170

Targeting IL-17 and Th17 cells in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.170

The IL-23/IL-17 axis in inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.170

IL-23 in the pathogenesis of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.170

Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.170

Abundant expression of the interleukin (IL)23 subunit p19, but low levels of bioactive IL23 in the rheumatoid synovium: differential expression and Toll-like receptor-(TLR) dependent regulation of the IL23 subunits, p19 and p40, in rheumatoid arthri

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.170

Monocyte derived interleukin (IL)-23 is an important determinant of synovial IL-17A expression in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.170

IL-12 and IL-23: master regulators of innate and adaptive immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.170

The clinical role of IL-23p19 in patients with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.170

IL-23 promotes osteoclast formation by up-regulation of receptor activator of NF-kappaB (RANK) expression in myeloid precursor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.170

IL-23 induces receptor activator of NF-kappaB ligand expression in fibroblast-like synoviocytes via STAT3 and NF-kappaB signal pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.170

Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.170

IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.170

Ubiquitous transgenic expression of the IL-23 subunit p19 induces multiorgan inflammation, runting, infertility, and premature death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.170

Interleukin 27 attenuates collagen-induced arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.170

IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.170

Cytokines that regulate autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.170

Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.170

Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.170

New directions in the basic and translational biology of interleukin-27.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.170

Lipopolysaccharide-mediated IL-10 transcriptional regulation requires sequential induction of type I IFNs and IL-27 in macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.170

Suppression of TNF-α and IL-1 signaling identifies a mechanism of homeostatic regulation of macrophages by IL-27

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.170

Local expression of interleukin-27 ameliorates collagen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.170

The inhibitory cytokine IL-35 contributes to regulatory T-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.170

IL-35-mediated induction of a potent regulatory T cell population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.170

IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.170

IL-35 stimulation of CD39+ regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.170

Induction of antinuclear antibodies in patients with rheumatoid arthritis receiving treatment with human recombinant interferon gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.170

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.170

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.170

LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.170

Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.170

Clinical significance of IL-18, IL-15, IL-12 and TNF-alpha measurement in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.170

Role of Th17 cells in human autoimmune arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.170

Interleukin (IL)-23 p19 expression induced by IL-1beta in human fibroblast-like synoviocytes with rheumatoid arthritis via active nuclear factor-kappaB and AP-1 dependent pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.170

Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.170

Active immunization against IL-23p19 improves experimental arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.170

IL-27 induces a Th1 immune response and susceptibility to experimental arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.170

Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.170

Brief report: a phase IIa, randomized, double-blind, placebo-controlled trial of apilimod mesylate, an interleukin-12/interleukin-23 inhibitor, in patients with rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.170

Interferon gamma in rheumatoid arthritis--a double blind study comparing human recombinant interferon gamma with placebo.

31 March 2020

1 reference

12 December 2020

Interleukin-27 inhibits human osteoclastogenesis by abrogating RANKL-mediated induction of nuclear factor of activated T cells c1 and suppressing proximal RANK signaling.

1 reference

12 December 2020

Collagen induced arthritis as an experimental model for rheumatoid arthritis. Immunogenetics, pathogenesis and autoimmunity

1 reference

12 December 2020

Dual role of IL-12 in early and late stages of murine collagen type II arthritis

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRRHEUM.2012.170

1 reference

PubMed ID

23090510

Dimensions Publication ID

27 August 2017

0 references

1 reference

PubMed ID

23090510